Chemomab Therapeutics Ltd DRC (NASDAQ:CMMB) — Stock Price
Chemomab Therapeutics Ltd DRC (NASDAQ:CMMB) is currently trading at $1.89 USD, down 2.07% today. Over the past 52 weeks, shares have ranged between $0.89 and $3.50. This page tracks Chemomab Therapeutics Ltd DRC's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Chemomab Therapeutics Ltd DRC (CMMB) total market value.
Chemomab Therapeutics Ltd DRC (CMMB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Chemomab Therapeutics Ltd DRC's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Chemomab Therapeutics Ltd DRC Income Statement — Revenue, Profit & Earnings by Year
Chemomab Therapeutics Ltd DRC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $70.56K | $53.25K | $66.83K | $57.77K | $34.02K |
| Gross Profit | $-70.56K | $-53.25K | $-66.83K | $-57.77K | $-34.02K |
| Research & Development | $5.88 Million | $11.33K | $18.38 Million | $16.98 Million | $6.33 Million |
| SG&A | $3.73 Million | $3.41K | $7.08 Million | $11.56 Million | $6.03 Million |
| Total Operating Expenses | $9.57 Million | $14.74 Million | $25.46 Million | $28.53 Million | $12.37 Million |
| Operating Income | $-9.64 Million | $-14.74 Million | $-25.46 Million | $-28.53 Million | $-12.37 Million |
| EBITDA | $-9.57 Million | $-13.96 Million | $-25.39 Million | $-28.48 Million | $-12.33 Million |
| EBIT | $-9.64 Million | $-14.01 Million | $-25.46 Million | $-28.53 Million | $-12.37 Million |
| Interest Expense | — | — | — | $353.00K | $111.08K |
| Income Before Tax | $-9.07 Million | $-13.95 Million | $-24.22 Million | $-28.18 Million | $-12.48 Million |
| Income Tax Expense | — | — | $-1.00 | $-534.00K | $77.00K |
| Net Income | $-9.07 Million | $-13.95 Million | $-24.22 Million | $-27.65 Million | $-12.48 Million |
Chemomab Therapeutics Ltd DRC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Chemomab Therapeutics Ltd DRC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $13.81 Million | $16.96 Million | $22.15 Million | $43.06 Million | $64.35 Million |
| Total Current Assets | $13.42 Million | $16.04 Million | $20.90 Million | $41.74 Million | $62.69 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $2.80 Million | $8.20 Million | $10.49 Million | $26.37 Million | $45.98 Million |
| Net Receivables | $3.06 Million | $263.00K | $289.00K | $459.00K | $179.00K |
| Inventory | — | $1.00 | $-1.04 Million | — | $-1.35 Million |
| Property, Plant & Equipment | — | — | — | $594.00K | $702.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $1.48 Million | $3.43 Million | $5.15 Million | $6.84 Million | $2.89 Million |
| Total Current Liabilities | $1.48 Million | $3.22 Million | $4.84 Million | $6.75 Million | $2.65 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-7.56 Million | $-5.75 Million | $-8.90 Million | $-13.30 Million | $-14.34 Million |
| Total Stockholder Equity | $12.33 Million | $13.54 Million | $17.00 Million | $36.22 Million | $61.47 Million |
| Retained Earnings | $-111.62 Million | $-102.62 Million | $-88.68 Million | $-63.82 Million | $-36.17 Million |
Chemomab Therapeutics Ltd DRC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Chemomab Therapeutics Ltd DRC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-11.22 Million | $-15.46 Million | $-23.55 Million | $-20.29 Million | $-12.38 Million |
| Capital Expenditures | $3.03K | $4.96 | $2.99K | $67.73K | $239.17K |
| Free Cash Flow | $-11.22 Million | $-15.46 Million | $-23.55 Million | $-20.36 Million | $-12.62 Million |
| Investing Cash Flow | $5.43 Million | $2.31 Million | $15.84 Million | $19.46 Million | $-45.22 Million |
| Financing Cash Flow | $7.21 Million | $9.91 Million | $3.49 Million | $-804.84K | $61.12 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $623.00K | $617.00K | $1.49 Million | $3.21 Million | $2.02 Million |
| Depreciation | $70.56K | $53.25K | $66.83K | $57.77K | $34.02K |
| Change in Cash | $1.42 Million | $-3.22 Million | $-4.23 Million | $-47.57 Million | $55.77 Million |
Chemomab Therapeutics Ltd DRC Earnings History — EPS Actual vs. Analyst Estimates
Track Chemomab Therapeutics Ltd DRC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | 0.00 | -0.01 | +70.00% |
| Nov 07, 2025 | 0.00 | -0.01 | +20.00% |
| Aug 14, 2025 | -0.02 | -0.10 | +84.00% |
| May 07, 2025 | -0.01 | -0.01 | +30.00% |
| Mar 05, 2025 | -0.01 | -0.01 | +20.00% |
| Nov 14, 2024 | -0.01 | -0.01 | +0.00% |
| Aug 21, 2024 | -0.26 | -0.01 | -2500.00% |
| May 09, 2024 | -0.28 | -0.03 | -817.67% |